Form 4: Paragon 28 Director Sells Shares Under 10b5-1 Trading Plan

Kristina Wright, a director at Paragon 28, sold 4,181 shares of common stock at $10 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Kristina Wright, a director at Paragon 28, sold 4,181 shares of the company's common stock.
• The sale occurred on November 13, 2024, at a price of $10 per share.
• This transaction was executed under a Rule 10b5-1 trading plan that was adopted on March 8, 2024.
• Following the sale, Ms. Wright beneficially owns 34,478 shares of Paragon 28 common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider trading activity and is common for publicly traded companies. It does not indicate any specific trend in the medical device industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The use of a 10b5-1 trading plan is a common method for insiders to sell shares while avoiding accusations of trading on non-public information.
• The volume of shares sold is relatively small compared to the total outstanding shares of the company.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder sentiment, but it is unlikely to be significant given the pre-arranged nature of the transaction.

Key Dates

Keywords

Paragon 28, insider trading, Form 4, stock sale, Rule 10b5-1, director, equity securities